Most refusals fall into four structural buckets: the benefit was never purchased, the request was reviewed under an indication the plan excludes, the required review was never filed, or the claim reached the wrong payer entirely. Which bucket applies is usually printed on the notice, and each one has a different remedy.
By Dr. Frank Comstock, MD, FACEP
Read the notice against the indication that was submitted
Tirzepatide sold as Zepbound carries two approved uses. One is reducing and maintaining body weight in adults with obesity, or adults with overweight plus a weight-related condition. The other is treating moderate to severe obstructive sleep apnea in adults with obesity, an indication supported by a randomized trial in that population and described by the agency as the first drug clearance for the condition.
Pharmacy benefits are drafted around categories of use, not molecules, so the indication attached to the request decides which rule set the reviewer opens. A refusal that quotes a weight-management exclusion is telling the reader something narrow: that one door is shut. It says nothing on its own about the other. Confirming which indication was actually submitted is therefore the first diagnostic step, and it is one that gets skipped constantly.
Reading how the two indications are described in plain language helps before drafting anything, and those descriptions are easier to find on provider pages than inside a denial letter. Telehealth names such as Henry Meds, Ro and HealthRX each keep a page on Zepbound that spells out its approved uses next to their own programs, which makes it quick to confirm whether a request was even framed under the indication the plan was judging. Getting that straight first prevents an appeal aimed at the wrong rule set.
Bucket one: the benefit was never bought
Anthem is a Blue Cross Blue Shield licensee, locally operated in the states where it holds the license and sitting under the Elevance Health corporate umbrella. Most large employers self-fund, so the employer pays the claims and the licensee administers the design the employer chose. When a plan sponsor declines to buy coverage for a drug category, no clinical file will change the outcome, because nothing was misapplied.
The tell is language about plan exclusions and benefit design rather than medical necessity. That wording moves the problem from documentation to purchasing. It also means the useful counterparty is the employer’s benefits team, not the pharmacy help line.
Bucket two: the required review never happened
Where a drug sits behind prior authorization, a claim submitted without an approved authorization on file rejects at the pharmacy before any human looks at it. This is a process gap, not a judgment, and it is common when a prescription moves between offices or when an earlier approval lapsed quietly. The fix is procedural: confirm what the plan requires, confirm the prescribing office filed it, and confirm the approval is still inside its effective dates.
Bucket three: documentation did not meet the plan’s own written standard
Reviewers compare a file against a published criteria document. Refusals in this bucket cite a specific unmet element, and the remedy is to produce the record that answers that exact element, dated and in the chart. Guessing at the standard wastes weeks, because the criteria vary between plan sponsors and between years. The criteria document behind the drug list is the only version that governs a given request, and members can ask for it.
Bucket four: the claim went to the wrong place
Benefits split. Some items adjudicate under the pharmacy benefit and some under the medical benefit, and a request routed to the wrong one can reject for reasons that have nothing to do with the drug. The same thing happens when a member holds coverage through one licensee and fills in a state served by another, or when secondary coverage is billed first. These rejections look clinical and are administrative.
| What the notice says | What it usually means | What actually moves it |
|---|---|---|
| Excluded under the plan | The sponsor did not buy that category | Employer benefits team, or a different indication |
| Prior authorization required | No approval was on file at fill time | Prescribing office files the request |
| Criteria not met | One named element is missing from the record | Dated chart evidence for that element |
| Not a covered benefit at this pharmacy | Channel or network mismatch | Confirm pharmacy benefit versus medical benefit |
| Quantity or days supply exceeded | Dispensing limit tripped, not a refusal of the drug | Correct the quantity on the prescription |
What a plan is required to tell you
Federal rules give members the right to a written explanation of an adverse benefit determination, including the specific reason and the rule relied on, plus notice of appeal rights and their deadlines. That written statement is worth more than any phone summary, because it is what an appeal or an independent external review will be measured against later. Verbal explanations drift; the letter does not.
When the refusal is genuinely final
Where the exclusion is drafted around the molecule rather than around weight management, both doors are closed and the question turns into a pricing question. Manufacturer self-pay pharmacies operated by Eli Lilly and Novo Nordisk publish figures for the approved products, and published cash prices from telehealth practices including Ro, Hims and Hers, LifeMD and formblends.com differ mainly in what the monthly figure includes. Programs built on compounded preparations should be read knowing that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality.
Questions people ask
Can the same prescription be resubmitted under the other indication?
A new request under a different indication is a different clinical claim and needs the diagnosis and workup that indication requires. It is not a relabeling exercise. Where the condition is genuinely present and documented, though, it is reviewed against its own criteria rather than the weight-management ones.
Why did the pharmacy reject it before anyone reviewed the case?
Pharmacy claims adjudicate in seconds against the plan’s electronic rules. A rejection at the counter reflects what those rules see at that moment, such as a missing authorization or a quantity limit. It is not a clinical determination, and it is not the decision an appeal would address.
Does a denial for one family member predict another’s result?
No. Two people at the same employer can hold different plan options, and two employers using the same licensee can buy entirely different drug benefits. Comparing outcomes across households produces false confidence in both directions. Only the plan document that applies to the member matters.
How long does the plan have to respond?
Federal standards set outer limits for authorization decisions and for appeals, with shorter clocks on urgent requests where delay would jeopardize health. The notice should state the applicable timeframe. Missed deadlines on the plan’s side can matter later, so dated proof of every submission is worth keeping from the first day.
